Didrik F. Vestrheim, Norway
Norwegian Institute of Public Health Department for infection control and vaccinesAuthor Of 3 Presentations
DEATH OF INVASIVE PNEUMOCOCCAL DISEASE IN RISK-GROUPS - A NATION-WIDE NORWEGIAN COHORT STUDY (ID 986)
MEDICAL RISK GROUPS BENEFIT FROM INDIRECT EFFECTS OF PCV13: A NATION-WIDE NORWEGIAN COHORT STUDY (ID 763)
Abstract
Background
We investigated indirect effects of PCV13 use in the childhood immunization programme in Norway on the incidence of invasive pneumococcal disease (IPD) in medical risk groups.
Methods
Our cohort included all Norwegian inhabitants aged ≥5 years during 2009-2017. We linked hospital discharge diagnoses (ICD-10 codes) from the Norwegian Patient Register with IPD notifications from the Norwegian Surveillance System for Communicable Diseases (n=5535). The cohort was stratified in risk-groups based on ICD-10 codes. We calculated incidences and annual changes (1-incidence rate ratios) for the years since PVC13 introduction (2011).
Results
The annual change in PCV13-type IPD was similar between risk groups (Overall, 19% [95%CI 17-22]). Non-PCV13 IPD increased on average by 4% [2-6] yearly (range 2-4% between groups). The overall change in IPD was non-significantly lower in risk groups (2% [95%CI 0-4%]) compared to the no-risk group (7% [5-9%]) resulting from the higher non-PCV13 incidence (32/100,000 versus 4/100,000) and larger proportion of cases (median for 2009-2017: 72% and 50%, respectively).
Conclusions
Overall, the IPD incidence decreased after PCV13 introduction in childhood immunisation. The annual change was slightly lower in risk groups compared to the no-risk group due to the dominance of non-PCV13 cases among risk groups and its substantially higher incidence.